Serina Therapeutics (SER) said Wednesday it sold its UniverXome subsidiary.
The deal, which was finalized on Dec. 23, cut $11.2 million in associated subsidiary-level debt, Serina said, adding it now has a debt-free balance sheet.
The unit was set up before Serina's reverse merger with AgeX Therapeutics in March 2024 to hold the legacy assets of the predecessor company, Serina said.